Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.71 +2.4%	$13.30	$9.57 ▼ $30.41	$2.17B	0.89	1.48 million shs	1.82 million shs
CGON CG Oncology	$25.43 +0.3%	$23.40	$14.80 ▼ $40.47	$1.94B	1.08	822,527 shs	1.23 million shs
GMTX Gemini Therapeutics	$47.09 +3.0%	$46.22	$1.16 ▼ $14.10	$2.04B	-0.12	189,291 shs	306,342 shs
MNMD Mind Medicine (MindMed)	$6.60 +0.8%	$6.12	$4.70 ▼ $10.44	$497.43M	2.52	1.37 million shs	660,046 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+2.88%	+15.77%	+19.19%	-23.11%	-38.74%
CGON CG Oncology	+4.88%	+4.98%	+26.06%	-11.12%	-9.50%
GMTX Gemini Therapeutics	-1.34%	+5.01%	+13.56%	-15.47%	+43.62%
MNMD Mind Medicine (MindMed)	+0.15%	+1.39%	+16.96%	-33.77%	-27.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.3501 of 5 stars	3.3	1.0	0.0	3.4	2.1	2.5	0.0
CGON CG Oncology	2.2904 of 5 stars	4.5	1.0	0.0	0.0	2.6	0.8	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	1.9625 of 5 stars	3.7	1.0	0.0	0.0	2.8	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.67	Moderate Buy	$42.13	168.14% Upside
CGON CG Oncology	3.00	Buy	$58.56	130.26% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	3.31	Buy	$25.11	280.47% Upside

Current Analyst Ratings Breakdown

Latest MNMD, ARWR, CGON, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/13/2025	MNMD Mind Medicine (MindMed)	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/9/2025	MNMD Mind Medicine (MindMed)	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/29/2025	CGON CG Oncology	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00
4/28/2025	CGON CG Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$75.00 ➝ $75.00
4/28/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/16/2025	CGON CG Oncology	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$23.00
3/31/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/25/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00

(Data available from 5/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.98	N/A	N/A	$1.54 per share	10.20
CGON CG Oncology	$1.14M	1,701.78	N/A	N/A	($1.94) per share	-13.11
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	$1.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	N/A
CGON CG Oncology	-$48.61M	-$1.51	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
MNMD Mind Medicine (MindMed)	-$95.73M	-$1.29	N/A	N/A	N/A	N/A	-47.56%	-35.55%	N/A

Latest MNMD, ARWR, CGON, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	MNMD Mind Medicine (MindMed)	-$0.36	-$0.35	+$0.01	-$0.35	N/A	N/A
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million
3/6/2025	Q4 2024	MNMD Mind Medicine (MindMed)	-$0.33	-$0.41	-$0.08	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
MNMD Mind Medicine (MindMed)	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
CGON CG Oncology	N/A	35.32	35.32
GMTX Gemini Therapeutics	N/A	71.49	71.49
MNMD Mind Medicine (MindMed)	0.09	9.00	9.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
CGON CG Oncology	26.56%
GMTX Gemini Therapeutics	75.42%
MNMD Mind Medicine (MindMed)	27.91%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
CGON CG Oncology	7.40%
GMTX Gemini Therapeutics	12.90%
MNMD Mind Medicine (MindMed)	2.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
CGON CG Oncology	61	76.22 million	N/A	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
MNMD Mind Medicine (MindMed)	40	75.37 million	71.68 million	Optionable

MNMD, ARWR, CGON, and GMTX Headlines

Recent News About These Companies

Cantor Fitzgerald Forecasts MNMD FY2025 Earnings

May 16 at 6:28 AM | marketbeat.com

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Given Consensus Rating of "Buy" by Brokerages

May 15 at 2:24 AM | americanbankingnews.com

Does Mind Medicine MindMed (MNMD) Have the Potential to Rally 279.84% as Wall Street Analysts Expect?

May 13 at 11:01 AM | zacks.com

Why Mind Medicine (MindMed) Inc.’s (MNMD) Stock Is Up 5.37%

May 12, 2025 | aaii.com

Mind Medicine (MindMed) (NASDAQ:MNMD) Receives Buy Rating from Chardan Capital

May 12, 2025 | americanbankingnews.com

Chardan Capital Reaffirms "Buy" Rating for Mind Medicine (MindMed) (NASDAQ:MNMD)

May 11, 2025 | marketbeat.com

Driehaus Capital Management LLC Cuts Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 11, 2025 | marketbeat.com

Earnings call transcript: MindMed Q1 2025 results show mixed signals

May 10, 2025 | uk.investing.com

Deep Track Capital LP Has $19.60 Million Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 9, 2025 | marketbeat.com

Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript

May 8, 2025 | seekingalpha.com

MindMed Reports First Quarter 2025 Financial Results and Recent Business Updates

May 8, 2025 | businesswire.com

Blackstone Inc. Trims Stock Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 8, 2025 | marketbeat.com

Mind Medicine Q1 2025 Earnings Preview

May 7, 2025 | msn.com

Allostery Investments LP Invests $905,000 in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 4, 2025 | marketbeat.com

Ally Bridge Group NY LLC Sells 458,233 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

May 4, 2025 | marketbeat.com

Mind Medicine (MindMed) (MNMD) to Release Earnings on Thursday

May 3, 2025 | marketbeat.com

Tri Locum Partners LP Decreases Position in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

April 29, 2025 | marketbeat.com

MindMed to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | businesswire.com

Institutional investors own a significant stake of 50% in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

April 24, 2025 | finance.yahoo.com

Marshall Wace LLP Purchases 213,526 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

April 23, 2025 | marketbeat.com

Geode Capital Management LLC Acquires 45,386 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)

April 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNMD, ARWR, CGON, and GMTX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.71 +0.37 (+2.41%)

Closing price 04:00 PM Eastern

Extended Trading

$15.49 -0.22 (-1.40%)

As of 07:44 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

CG Oncology NASDAQ:CGON

$25.43 +0.08 (+0.32%)

Closing price 04:00 PM Eastern

Extended Trading

$25.00 -0.43 (-1.69%)

As of 06:36 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Gemini Therapeutics NASDAQ:GMTX

$47.09 +1.36 (+2.97%)

As of 05/15/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Mind Medicine (MindMed) NASDAQ:MNMD

$6.60 +0.05 (+0.76%)

Closing price 04:00 PM Eastern

Extended Trading

$6.46 -0.14 (-2.05%)

As of 07:56 PM Eastern

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time